ViewRay, Inc. (VRAYQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ViewRay, Inc. (VRAYQ) with AI Score 60/100 (Hold). ViewRay, Inc. specializes in MRI-guided radiation therapy systems for cancer treatment. The company filed for Chapter 7 bankruptcy after a prior Chapter 11 filing in 2023. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026ViewRay, Inc. (VRAYQ) Healthcare & Pipeline Overview
ViewRay, Inc., designs, manufactures, and markets MRI-guided radiation therapy systems, notably the MRIdian, used in cancer treatment. Serving university hospitals and cancer centers internationally, ViewRay filed for Chapter 7 bankruptcy in October 2023. Investors should note the company's current financial instability and OTC market status.
Investment Thesis
ViewRay, Inc. presents a challenging investment landscape due to its Chapter 7 bankruptcy status as of October 2023. The company's innovative MRIdian system, which integrates MRI-guided radiation therapy, had potential in the cancer treatment market, evidenced by its installations in various hospitals and cancer centers globally. However, the company's negative profit margin of -105.2% and reliance on debt financing contributed to its financial instability. Potential investors should carefully consider the implications of the bankruptcy proceedings, including the potential liquidation of assets and the uncertainty surrounding any future operations or restructuring efforts. The company's stock now trades on the OTC market, adding further complexity and risk for investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B, reflecting the company's distressed financial situation.
- Negative P/E ratio of -0.04, indicating losses and making traditional valuation difficult.
- Profit Margin of -105.2%, highlighting significant financial losses.
- Gross Margin of 9.8%, suggesting challenges in maintaining profitability even before accounting for operating expenses.
- Beta of 1.34, indicating higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Innovative MRIdian MRI-guided radiation therapy system.
- Potential for precise and effective cancer treatment.
- Established presence in key international markets.
- Strong relationships with leading cancer centers (status uncertain).
Weaknesses
- Chapter 7 bankruptcy filing.
- Negative profit margin and financial losses.
- High debt levels (likely to be restructured or eliminated in bankruptcy).
- Dependence on capital-intensive equipment sales.
Catalysts
- Potential for restructuring or asset sales during the Chapter 7 bankruptcy proceedings.
- Any developments in cancer treatment technologies that could indirectly impact the value of ViewRay's intellectual property.
- Legal outcomes related to bankruptcy proceedings.
Risks
- Chapter 7 bankruptcy proceedings may result in liquidation of assets and loss of investment.
- Delisting from the OTC market due to non-compliance with regulations.
- Loss of key personnel and expertise.
- Erosion of customer relationships and market share.
- Limited access to capital and financing.
Growth Opportunities
- Advancements in MRI-Guided Radiation Therapy: Continuous innovation in MRI-guided radiation therapy could lead to more precise and effective cancer treatments. This includes improvements in imaging resolution, treatment planning software, and radiation delivery techniques. The market for advanced radiation therapy is projected to grow, driven by the increasing prevalence of cancer and the demand for less invasive treatment options. However, ViewRay's bankruptcy status casts doubt on its ability to capitalize on these advancements.
- Expansion into Emerging Markets: Expanding the availability of MRIdian systems in emerging markets, where access to advanced cancer treatment is limited, could drive growth. These markets often have a growing middle class and increasing healthcare spending, creating opportunities for medical device companies. However, ViewRay's current financial situation may hinder its ability to invest in international expansion.
- Strategic Partnerships and Collaborations: Collaborating with leading cancer centers and research institutions could accelerate the development and adoption of MRIdian technology. These partnerships could provide access to clinical expertise, patient populations, and funding opportunities. However, ViewRay's bankruptcy may make it difficult to attract and maintain strategic partnerships.
- Development of New Clinical Applications: Exploring new clinical applications for MRIdian technology beyond its current use in treating solid tumors could expand its market potential. This could include using MRI-guided radiation therapy to treat other types of cancer or to deliver targeted therapies. However, ViewRay's financial constraints may limit its ability to invest in research and development.
- Service and Maintenance Contracts: Generating recurring revenue through service and maintenance contracts for installed MRIdian systems could provide a stable source of income. These contracts could include preventative maintenance, software updates, and technical support. However, the long-term viability of these contracts depends on ViewRay's ability to continue supporting its installed base.
Opportunities
- Advancements in MRI-guided radiation therapy technology.
- Expansion into emerging markets.
- Strategic partnerships and collaborations.
- Development of new clinical applications.
Threats
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory hurdles.
- Economic downturns affecting hospital capital spending.
Competitive Advantages
- Proprietary MRI-guided radiation therapy technology.
- Established relationships with leading cancer centers.
- Global distribution network.
- Patents protecting key innovations (status uncertain due to bankruptcy).
About VRAYQ
ViewRay, Inc., established in 2004 and headquartered in Denver, Colorado, focuses on developing and commercializing MRI-guided radiation therapy systems. Its flagship product, MRIdian, is designed to improve the precision and efficacy of cancer treatment by integrating real-time MRI imaging with radiation delivery. This technology aims to address challenges such as beam distortion and skin toxicity, offering a more targeted approach to radiation therapy. ViewRay serves a global market, including university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. The company utilizes a direct sales force and distributors to reach its customer base across the United States, Italy, France, Taiwan, and the United Kingdom. However, ViewRay's operations have been significantly impacted by its recent bankruptcy filings. On July 16, 2023, ViewRay, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Subsequently, on October 26, 2023, the case was converted to Chapter 7, indicating a shift from reorganization efforts to liquidation.
What They Do
- Designs, manufactures, and markets MRI-guided radiation therapy systems.
- Offers MRIdian, an MRI-guided radiation therapy system that addresses beam distortion and skin toxicity.
- Provides solutions for imaging and treating cancer patients.
- Serves university research and teaching hospitals.
- Serves community hospitals and private practices.
- Serves government institutions and freestanding cancer centers.
- Operates in the United States, Italy, France, Taiwan, and the United Kingdom.
Business Model
- Sales of MRIdian MRI-guided radiation therapy systems.
- Service and maintenance contracts for installed systems.
- Partnerships with hospitals and cancer centers.
- International distribution through direct sales force and distributors.
Industry Context
ViewRay, Inc. operates within the medical devices industry, specifically focusing on radiation therapy systems. The industry is characterized by technological advancements, increasing demand for non-invasive cancer treatments, and stringent regulatory requirements. Competitors include companies like Accuray (ABMT), which also develop radiation therapy technologies. The market for advanced radiation therapy systems is driven by the growing prevalence of cancer and the desire for more precise and effective treatment options. However, ViewRay's bankruptcy introduces uncertainty about its ability to compete and maintain its market position.
Key Customers
- University research and teaching hospitals.
- Community hospitals.
- Private practices.
- Government institutions.
- Freestanding cancer centers.
Financials
Chart & Info
ViewRay, Inc. (VRAYQ) stock price: Price data unavailable
Latest News
No recent news available for VRAYQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRAYQ.
Price Targets
Wall Street price target analysis for VRAYQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates VRAYQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul Ziegler Jr.
Unknown
Information on Paul Ziegler Jr.'s background is not available in the provided data. Therefore, a detailed career history, education, previous roles, and credentials cannot be provided. Further research would be needed to compile a comprehensive biography.
Track Record: Due to the lack of available information on Paul Ziegler Jr.'s background and specific achievements at ViewRay, Inc., it is not possible to provide a detailed track record of key achievements, strategic decisions, or company milestones under his leadership. The company's recent bankruptcy filing overshadows any potential positive contributions.
VRAYQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ViewRay (VRAYQ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, in bankruptcy, or have chosen not to comply with OTC Markets' higher reporting standards. Investing in OTC Other stocks carries significant risks due to the limited information available and the potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited information and disclosure requirements.
- Low liquidity and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Limited regulatory oversight.
- Verify the company's current legal status and any ongoing legal proceedings.
- Review any available financial statements, even if unaudited.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's ability to continue as a going concern.
- Consult with a qualified financial advisor before investing.
- Be aware of the risks associated with OTC Other stocks.
- Previous operation as a publicly traded company on a major exchange (prior to bankruptcy).
- Existing intellectual property and patents (though value may be impaired).
- Prior relationships with established hospitals and cancer centers (status uncertain).
- Presence of a management team (though effectiveness is questionable).
What Investors Ask About ViewRay, Inc. (VRAYQ) — Healthcare
What does ViewRay, Inc. do?
ViewRay, Inc. designs, manufactures, and markets MRI-guided radiation therapy systems, primarily the MRIdian. This system integrates MRI technology with radiation therapy to provide real-time imaging during cancer treatment, aiming to improve precision and reduce side effects. However, the company filed for Chapter 7 bankruptcy in October 2023, impacting its operations and future prospects. The company's systems are used in hospitals and cancer centers internationally.
What do analysts say about VRAYQ stock?
Due to ViewRay, Inc.'s Chapter 7 bankruptcy and its trading status on the OTC market, formal analyst coverage is likely limited or non-existent. Traditional valuation metrics such as price targets and buy/sell ratings are unlikely to be available. Investors should rely on their own due diligence and be aware of the significant risks associated with investing in a bankrupt company trading on the OTC market. The focus should be on understanding the bankruptcy proceedings and potential outcomes for shareholders.
What are the main risks for VRAYQ?
The primary risk for VRAYQ is its Chapter 7 bankruptcy status, which could lead to the liquidation of assets and a complete loss of investment for shareholders. Additional risks include the limited liquidity and transparency associated with trading on the OTC market, potential delisting from the OTC market, and the uncertainty surrounding any future operations or restructuring efforts. Investors should carefully consider these risks before investing in VRAYQ.
What are the key factors to evaluate for VRAYQ?
ViewRay, Inc. (VRAYQ) currently holds an AI score of 60/100, indicating moderate score. Key strength: Innovative MRIdian MRI-guided radiation therapy system. Primary risk to monitor: Chapter 7 bankruptcy proceedings may result in liquidation of assets and loss of investment. This is not financial advice.
How frequently does VRAYQ data refresh on this page?
VRAYQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VRAYQ's recent stock price performance?
Recent price movement in ViewRay, Inc. (VRAYQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative MRIdian MRI-guided radiation therapy system. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VRAYQ overvalued or undervalued right now?
Determining whether ViewRay, Inc. (VRAYQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VRAYQ?
Before investing in ViewRay, Inc. (VRAYQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be incomplete due to the company's bankruptcy status.
- The company's financial situation is highly volatile and subject to change.
- OTC market data may be less reliable than data from major exchanges.